Current Surgical Principle for Uterine Cervical Cancer of Stages Ia2, Ib1, and IIa1 in Japan: A Survey of the Japanese Gynecologic Oncology Group

2013 ◽  
Vol 23 (9) ◽  
pp. 1655-1662 ◽  
Author(s):  
Mikio Mikami ◽  
Yoichi Aoki ◽  
Masaru Sakamoto ◽  
Muneaki Shimada ◽  
Nobuhiro Takeshima ◽  
...  
Keyword(s):  
Cervical Cancer ◽  
Squamous Cell Carcinoma ◽  
Lymph Node ◽  
Cell Carcinoma ◽  
Gynecologic Oncology ◽  
Uterine Cervical Cancer ◽  
Gynecologic Oncology Group ◽  
Node Dissection ◽  
Oncology Group ◽  
Invasive Procedures

ObjectiveThe objective of this study was to determine the current operative principle of uterine cervical cancer of stages Ia2, Ib1, and IIa1 (International Federation of Gynecology and Obstetrics) in Japan by surveying member institutions of the Japanese Gynecologic Oncology Group (JGOG).MethodsWe conducted a survey to assess the current operative principle, including indications and treatment, at all 199 active member institutions of the JGOG.ResultsA total of 166 institutions (83.4%) responded to the survey. For Ia2 squamous cell carcinoma without the need to preserve fertility, modified radical hysterectomy was performed, and lymph node dissection was done in about 85%. At 60% of JGOG institutions, it was considered that less invasive procedures might be suitable. At the majority of JGOG institutions, radical surgery and lymph node dissection were considered necessary for stages Ib1 and IIa1 squamous cell carcinoma, with 70% considering that less invasive procedures might not be suitable.ConclusionsThis survey provides information regarding the current status of surgical principle for uterine cervical cancer (stages Ia2, Ib1, and IIa1) in Japan.

Surgical Principles for Managing Stage IB2, IIA2, and IIB Uterine Cervical Cancer (Bulky Tumors) in Japan: A Survey of the Japanese Gynecologic Oncology Group

2014 ◽  
Vol 24 (7) ◽  
pp. 1333-1340 ◽  
Author(s):  
Mikio Mikami ◽  
Yoichi Aoki ◽  
Masaru Sakamoto ◽  
Muneaki Shimada ◽  
Nobuhiro Takeshima ◽  
...  
Keyword(s):  
Cervical Cancer ◽  
High Risk ◽  
Cell Carcinoma ◽  
Gynecologic Oncology ◽  
Operative Management ◽  
Uterine Cervical Cancer ◽  
Active Member ◽  
Gynecologic Oncology Group ◽  
Oncology Group ◽  
Risk Patients

ObjectiveThe aim of this study was to determine the current operative management of International Federation of Gynecology and Obstetrics (FIGO) stage IB2, IIA2, and IIB uterine cervical cancer (bulky tumors) in Japan by surveying the member institutions of the Japanese Gynecologic Oncology Group.MethodsWe conducted a survey to assess current operative management, including indications and treatment, at all 199 active member institutions of the Japanese Gynecologic Oncology Group.ResultsA total of 166 institutions (83.4%) responded to the survey. For patients with stage IIB squamous cell carcinoma, 35.5% (59/166) of the institutions performed surgery. For stage IIB nonsquamous cell carcinoma, surgery was performed at 88 (53.7%) of 164 institutions. Neoadjuvant chemotherapy was provided by 75 (45.5%) of 165 institutions (actively in 44 and reluctantly in 31). At 101 (61.2%) of 165 institutions, para-aortic node dissection was performed as part of radical surgery in patients with any indications. At 96 (57.9%) of 166 institutions, high-risk patients underwent chemoradiotherapy after surgery. On the other hand, adjuvant chemotherapy was given to high-risk and intermediate-risk patients at 19.9% and 33.1% institutions, respectively. More than half of the 166 institutions considered the number of metastatic nodes (91/166, 54.8%) and tumor histology (116/166, 69.9%) when selecting adjuvant therapy.ConclusionsThis survey provided information regarding the current surgical management of uterine cervical cancer (stages IB2, IIA2, and IIA) in Japan.

Paclitaxel and Cisplatin as First-Line Therapy in Recurrent or Advanced Squamous Cell Carcinoma of the Cervix: A Gynecologic Oncology Group Study

1999 ◽  
Vol 17 (9) ◽  
pp. 2676-2676 ◽  
Author(s):  
Peter G. Rose ◽  
John A. Blessing ◽  
David M. Gershenson ◽  
Ramon McGehee
Keyword(s):  
Squamous Cell Carcinoma ◽  
Cell Carcinoma ◽  
Squamous Cell ◽  
Gynecologic Oncology ◽  
Phase Iii ◽  
Gynecologic Oncology Group ◽  
Oncology Group ◽  
First Line ◽  
First Line Therapy ◽  
Line Therapy

PURPOSE: On the basis of the activity of paclitaxel as a single agent in chemotherapy-naive squamous cell carcinoma of the cervix in a prior Gynecologic Oncology Group (GOG) trial, a phase II study of paclitaxel and cisplatin as first-line therapy was conducted by the GOG. PATIENTS AND METHODS: Eligibility included squamous cell cancer of the cervix not curable by surgery or radiation, measurable disease, WBC count ≥ 3,000/μL, platelet count ≥ 100,000/μL, serum creatinine ≥ 2 mg/100 mL, and adequate hepatic function. The starting dose was paclitaxel 135 mg/m2 infused over 24 hours followed by cisplatin 75 mg/m2 every 21 days. On the basis of toxicity, a dose escalation of paclitaxel to a maximum dose of 170 mg/m2/d was prescribed. RESULTS: Forty-seven patients were enrolled onto this study; 44 patients were assessable for toxicity and 41 for response. Forty (90.9%) had received prior radiation therapy. A median of six courses of chemotherapy was given (range, one to 10 courses). Neutropenia grade 3 (15.9%) and 4 (61.4%) was the most frequent severe adverse effect and was associated with fever in 13 patients (27.7%). Two patients (4.5%) died from neutropenic sepsis. Grade 4 thrombocytopenia occurred in 6.8% of patients. Of 41 assessable patients, five (12.2%) had complete responses and 14 (34.1%) had partial responses for an overall response rate of 46.3% (95% confidence interval, 30.7% to 62.6%). The median progression-free interval, was 5.4+ months (range, 0.3 to 22+ months) with a median survival of 10.0+ months (range, 0.9 to 22.2 months). Response was more frequent in patients with disease in nonirradiated sites (70% v 23%, P = .008). CONCLUSION: This regimen seems highly active in advanced and recurrent squamous cell carcinoma of the cervix and is currently being evaluated by the GOG in a phase III randomized study comparing the combination of paclitaxel and cisplatin with cisplatin alone.

Cisplatin plus gemcitabine in previously treated squamous cell carcinoma of the cervix: A phase II study of the Gynecologic Oncology Group

2006 ◽  
Vol 100 (2) ◽  
pp. 385-388 ◽  
Author(s):  
Cheryl A. Brewer ◽  
John A. Blessing ◽  
Robert A. Nagourney ◽  
D. Scott McMeekin ◽  
Shashikant Lele ◽  
...  
Keyword(s):  
Squamous Cell Carcinoma ◽  
Cell Carcinoma ◽  
Phase Ii ◽  
Squamous Cell ◽  
Phase Ii Study ◽  
Gynecologic Oncology ◽  
Gynecologic Oncology Group ◽  
Oncology Group ◽  
Previously Treated

Topotecan in Squamous Cell Carcinoma of the Cervix: A Phase II Study of the Gynecologic Oncology Group

2000 ◽  
Vol 77 (3) ◽  
pp. 446-449 ◽  
Author(s):  
Michael A. Bookman ◽  
John A. Blessing ◽  
Parviz Hanjani ◽  
Thomas J. Herzog ◽  
Willie A. Andersen
Keyword(s):  
Squamous Cell Carcinoma ◽  
Cell Carcinoma ◽  
Phase Ii ◽  
Squamous Cell ◽  
Phase Ii Study ◽  
Gynecologic Oncology ◽  
Gynecologic Oncology Group ◽  
Oncology Group
Sign in / Sign up

Export Citation Format

Share Document